Milk casein-derived Met-Lys-Pro peptide , 200 μg/day,
does it really help with Improved global cognition measured by the ADAS-cog total score at 24 weeks?
research showsGrade D. In the 268-person, 24-week randomized trial, ADAS-cog total score changed from 4.08±2.17 to 3.18±1.88 with MKP and from 4.10±2.10 to 3.43±2.10 with placebo; the baseline-adjusted between-group P value was .302 and effect size d=.12. Improvement in both groups reflects repeat testing, not a specific MKP effect.
ads claimImprovement in both groups on a repeated test cannot be assigned to the ingredient. A product effect requires superiority to placebo, and that between-group comparison was null at P=.302.
Useful facts when choosing a product
- MKP is the milk-casein-derived tripeptide Met-Lys-Pro.
- The daily dose was 200 μg and the control used dextrin tablets.
- The paper did not report a 95% CI for the primary endpoint.
Chamgap Semantic Classification Code
Candidate index · review held
F.milk-casein-derived-met-lys-pro-peptide.food.global-cognition-measured-by-the-adas-cog-total-score-at.improve.placeboFoods and beverages > Milk casein-derived Met-Lys-Pro peptide > Food consumption > global cognition measured by the ADAS-cog total score at > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The Japanese community trial randomized 268 adults aged at least 40 without dementia, 134/134, to MKP 200 μg/day or dextrin placebo for 24 weeks. The primary endpoint was ADAS-cog total score. Morinaga Milk supported the study and manufactured and supplied the MKP-containing casein hydrolysate and placebo tablets. N.Y., M.T., K.Y., and F.A. were Morinaga employees, and N.S. received a supervision fee from the company. No separate public cofunding, medical-writing, or publication support was reported. UMIN000032833 was disclosed June 4, 2018, before the planned June 7 start. Computer block randomization, masking of participants, physicians, assessors, and analysts, and intention-to-treat analysis were reported.
Why this is classified as D (30)
One robust 268-person manufacturer-supported trial was null on ADAS-cog total score but lacked a confidence interval excluding benefit, giving D with 30 points.
Counterpoint. A P=.022 Orientation subscale did not reverse failure of the global primary endpoint.
Rejudgment record. Cross-check applied — 268-person 24-week intention-to-treat multiply masked design, null ADAS-cog total score, and non-promotion of the positive Orientation subscale
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved ADAS-cog total score | D | The baseline-adjusted result was null, P=.302, d=.12. |
| Improved Orientation subscale | C | P=.022, but it does not override the null primary total score. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Yuda N et al. 2020 | Double-blind randomized placebo-controlled parallel trial | 268 randomized and analyzed by intention to treat (134/134) | Morinaga Milk study support and product manufacture/supply; four employee authors and one supervision-fee recipient | ADAS-cog total score at 24 weeks | 4.08±2.17 to 3.18±1.88 vs 4.10±2.10 to 3.43±2.10; baseline-adjusted P=.302, d=.12; no 95% CI reported | Primary global cognition endpoint |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Evidence date: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] No Benefit of Casein-Derived MKP for Global ADAS-cog Cognition — Evidence Grade D·30. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/mkp-casein-peptide-adas-cog-total-score/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.